Transforming Translational Research at the University of Bristol (CiC 2016)
Lead Research Organisation:
University of Bristol
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding. It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.
People |
ORCID iD |
| Description | Innovate UK Investment Accelerator (Massimo Antognozzi) |
| Amount | £150,000 (GBP) |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2018 |
| End | 07/2019 |
| Description | MRC Proximity to Discovery and Enterprise and Impact Development Fund (Jenny Bailey / Tristan Cogan) |
| Amount | £35,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2018 |
| End | 08/2018 |
| Description | MRC Confidence in Concept collaboration with DST and Semefab |
| Organisation | Semefab (Scotland) Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Development of novel silicon diode dosimetry devices for radiotherapy verification |
| Collaborator Contribution | Potential commercial partner |
| Impact | • £32,500 in kind support provided by DST/Semefab • Considering licencing IP to IBA |
| Start Year | 2017 |
| Description | MRC Confidence in Concept collaboration with Life Arc and Abzena (Richard Lee) |
| Organisation | Abzena plc |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Selective Calcineurin Inhibition for the Treatment of Corticosteroid Resistant Diseases |
| Collaborator Contribution | Abzena: discussions over scale up work LifeArc: supplied the resources, expertise and material to generate the CCR6 antibodies and provided access to their laboratories and generally assisted in the generation of the monoclonal antibody. They have 17 years' experience in therapeutic antibody development and dedicated laboratories for the generation of monoclonal therapeutic antibodies. They have a variety of robotic systems and assay systems to aid the development and engineering of antibodies and substantial protein chemistry and protein production facilities. |
| Impact | • £78,559 in kind support from LifeArc • Awarded £58,000 grant from National Eye Research Centre • Project selected as Bristol's application to Jules Thorne Biomedical Award 2018 - no formal costs at outline but approx. £1M • £53,000 from Moorfields BRC for top up project • Abzena in line for scale up work |
| Start Year | 2017 |
| Description | MRC Confidence in Concept collaboration with Life Arc and Abzena (Richard Lee) |
| Organisation | LifeArc |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Selective Calcineurin Inhibition for the Treatment of Corticosteroid Resistant Diseases |
| Collaborator Contribution | Abzena: discussions over scale up work LifeArc: supplied the resources, expertise and material to generate the CCR6 antibodies and provided access to their laboratories and generally assisted in the generation of the monoclonal antibody. They have 17 years' experience in therapeutic antibody development and dedicated laboratories for the generation of monoclonal therapeutic antibodies. They have a variety of robotic systems and assay systems to aid the development and engineering of antibodies and substantial protein chemistry and protein production facilities. |
| Impact | • £78,559 in kind support from LifeArc • Awarded £58,000 grant from National Eye Research Centre • Project selected as Bristol's application to Jules Thorne Biomedical Award 2018 - no formal costs at outline but approx. £1M • £53,000 from Moorfields BRC for top up project • Abzena in line for scale up work |
| Start Year | 2017 |
| Description | Med Chem contract with Domainex |
| Organisation | Domainex |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | A pathway to full clinical development of the first drug to treat genetic forms of Nephrotic Syndrome |
| Collaborator Contribution | Medicinal chemistry |
| Impact | N/A |
| Start Year | 2019 |
| Title | Development of novel clinical platelet function analyser |
| Description | Development of novel clinical platelet function analyser |
| IP Reference | P120007GB |
| Protection | Patent application published |
| Year Protection Granted | 2017 |
| Licensed | Commercial In Confidence |
| Impact | • Innovate UK ICURe project to validate technology in the workplace complete • UK priority patent application filed #P120007GB • NIHR i4i outline application planned |
| Company Name | Ceryx Medical |
| Description | Ceryx Medical is developing bioelectronics based on unique, patent protected, chip technology which is able to mimic nerve centres within the body called Central Pattern Generators (CPGs). These CPGs help to control a range of autonomic or rhythmical processes within the body such as peristalsis, heart rate and even walking. |
| Year Established | 2017 |
| Impact | N/A |
| Website | http://www.ceryxmedical.com/ |
| Company Name | FERRYX LIMITED |
| Description | Ferryx are developing a safe and effective probiotic to prevent or treat gastrointestinal inflammation. Unlike many conventional probiotics, our proprietary strain thrives in the inflamed gut and exerts anti-inflammatory effects. |
| Year Established | 2019 |
| Impact | Too early to record notable impacts. |
| Company Name | VITAMICA LIMITED |
| Description | Vitamica was established in early 2018 as a spin-out company from the University of Bristol. Taking optical technology from the School of Physics, the new company is beginning its journey towards commercialisation of a rapid and novel diagnostic method that has high potential for use in antimicrobial susceptibility testing. With a growing IP portfolio and an active approach to identifying opportunities in healthcare, veterinary and pharma sectors, Vitamica fully intends to make its mark as another successful company to originate from the University of Bristol. |
| Year Established | 2018 |
| Impact | • Awarded £13,000 Longitude Discovery Prize • Awarded £150,000 from Innovate UK Investment Accelerator • Applied for Biomedical Catalyst, £195K - unsuccessful • Innovate UK ICURe project to validate technology in the workplace complete • UK priority patent application filed #P123064GB • Spin out company, Vitamica, created • £200,000 of early stage investment into company • Currently undergoing another investment round • MRC P2D funding for student projects £4k • EPSRC NPIF grant - 3 month placement in company |
| Website | https://www.vitamica.co.uk/ |